DrStore Healthcare Services India has entered into a strategic partnership with TatvaCare’s Health & Wellness app GoodFlip to expand access to connected continuous glucose monitoring (CGM) technologies and strengthen India’s digital diabetes and metabolic care infrastructure. The collaboration brings together TRACKY, DrStore’s connected medical device brand that launched India’s first Bluetooth-enabled CGM system in 2025, and TatvaCare’s GoodFlip, an integrated digital platform focused on cardio-metabolic health. By tightly integrating hardware and software, the two companies aim to accelerate the shift from episodic testing to real-time, data-driven disease management across high-risk patient populations.
Under the partnership, TRACKY’s connected CGM devices will be deployed across TatvaCare’s digital care programmes and specialised clinical pathways, including diabetes, chronic kidney disease (CKD), post-transplant metabolic management and other complex metabolic disorders. The integration will enable real-time transmission of glucose data into the GoodFlip ecosystem, allowing clinicians to remotely track glucose trends, flag deteriorations earlier and intervene more proactively for patients spread across geographies. For individuals living with diabetes and related conditions, continuous data streams are expected to support more personalised therapy adjustments and improved treatment adherence.
The collaboration places particular emphasis on patient groups with high glycaemic variability, such as those with CKD and individuals requiring post-transplant metabolic management. These patients often experience sharp fluctuations in blood glucose due to immunosuppressive therapy, steroid use and multifactorial metabolic changes, making traditional intermittent finger-prick testing inadequate for precise control. Continuous glucose monitoring in such settings can help clinicians detect rapid swings, fine-tune insulin and other medications, and potentially reduce the risk of complications and hospitalisations.
TRACKY’s Bluetooth-connected CGM system, introduced in 2025, marked a significant milestone in India’s CGM technology landscape by moving glucose monitoring from standalone devices to a connected, platform-driven model. By enabling seamless, real-time data transfer to digital health platforms like GoodFlip, the technology supports a more integrated approach to metabolic health management that combines biosensing, analytics and remote clinical oversight. This transition aligns with the broader global trend of embedding continuous monitoring into routine chronic disease care.
“Continuous monitoring technologies are redefining how metabolic diseases are managed globally,” said Neeraj Katare, Founder of DrStore Healthcare Services India Private Limited. “With TRACKY, our vision has been to build a connected biosensing platform that integrates advanced medical devices with digital health ecosystems. Launching India’s first Bluetooth-connected CGM was an important step in that journey. As adoption of continuous monitoring accelerates, we see tremendous potential in building an integrated metabolic monitoring ecosystem that enables clinicians and patients to move from episodic testing to real-time, data-driven care.”
From TatvaCare’s perspective, the integration with TRACKY is intended to deepen the clinical utility of its digital health ecosystem and extend decision support to treating physicians. “Digital health platforms are playing an increasingly critical role in enabling more personalised and continuous care pathways,” said Manoj Balaji, Chief Executive Officer at TatvaCare. “By integrating TRACKY’s connected CGM technology within TatvaCare’s ecosystem, we aim to extend access to clinicians with deeper metabolic insights and enable patients to benefit from more proactive and technology-enabled disease management.”
For TRACKY, the tie-up fits into a broader roadmap to evolve from a glucose-centric solution to a comprehensive continuous metabolic monitoring platform. The company is developing next-generation technologies to monitor multiple metabolic and cardiovascular biomarkers in real time, enabling clinicians to gain a unified view of a patient’s metabolic health. Such multimodal biosensing could help manage complex cardiometabolic profiles and tailor interventions more precisely to individual risk patterns.
In parallel, TRACKY is exploring digital health applications that support metabolic therapy management, including emerging care models built around GLP-1–based weight-loss therapies. By combining connected biosensors, digital platforms and advanced data analytics, the company is positioning itself to enable a more holistic, personalised approach to metabolic care that spans diabetes, obesity and cardiovascular risk.
As the burden of metabolic diseases such as diabetes, obesity and cardiovascular disorders continues to rise, the convergence of connected medical devices, biosensing innovation and digital health platforms is expected to play a pivotal role in shifting health systems towards preventive, continuous and personalised care models. With continuous glucose monitoring gaining traction among healthcare providers, digital health platforms and specialised clinical programmes in India, integrated partnerships like that of TRACKY and TatvaCare signal how CGM technologies are increasingly becoming embedded within broader chronic disease management ecosystems.
